ELDER WILLIAM ROBERT 4

What Happened William Robert Elder, who serves as CervoMed’s Chief Financial Officer, General Counsel and Secretary, was granted an award of 30,000 shares on February 11, 2026. The award is reported at a $0 acquisition price (i.e., no cash paid) and is a derivative award where the underlying common shares will vest over time. This is a compensation award (not an open-market purchase or sale).

Key Details

• Transaction type: Grant / Award (code A) of 30,000 shares at $0.00 per share (reported as a derivative award) on 2026-02-11.
• Vesting: The shares underlying the award vest in 36 approximately equal monthly installments on the last calendar day of each month, commencing February 28, 2026 (per footnote).
• Filing: Form 4 filed 2026-02-13 for a reportable event on 2026-02-11 — filing appears timely.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• No 10b5-1 plan, tax-withholding, cashless exercise, or gift notation included in the provided notes.

Context This is a time‑based compensation award intended for retention or incentive; the shares will be delivered as they vest rather than representing an immediate market purchase or sale. Because the grant is priced at $0 on the report, there was no cash outlay by the insider at grant. For investors, such awards are routine executive compensation and do not by themselves indicate buying or selling sentiment until/if shares are later sold in the open market.